{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:49:59Z","timestamp":1793191799611,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006360","name":"Bundesministerium f\u00fcr Wirtschaft und Energie","doi-asserted-by":"publisher","award":["03THW10H09"],"award-info":[{"award-number":["03THW10H09"]}],"id":[{"id":"10.13039\/501100006360","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Chem"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Non-alcoholic steatohepatitis (NASH) - a hepatic manifestation of the metabolic syndrome - is a multifactorial disease with alarming global prevalence. It involves steatosis, inflammation and fibrosis in the liver, thus demanding multiple modes of action for robust therapeutic efficacy. Aiming to fuse complementary validated anti-NASH strategies in a single molecule, we have designed and systematically optimized a scaffold for triple activation of farnesoid X receptor (FXR), peroxisome proliferator-activated receptor (PPAR) \u03b1 and PPAR\u03b4. Pilot profiling of the resulting triple modulator demonstrated target engagement in native cellular settings and in mice, rendering it a suitable tool to probe the triple modulator concept in vivo. In DIO NASH in mice, the triple agonist counteracted hepatic inflammation and reversed hepatic fibrosis highlighting the potential of designed polypharmacology in NASH.<\/jats:p>","DOI":"10.1038\/s42004-020-00411-z","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T11:02:55Z","timestamp":1605265375000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A triple farnesoid X receptor and peroxisome proliferator-activated receptor \u03b1\/\u03b4 activator reverses hepatic fibrosis in diet-induced NASH in mice"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5187-6342","authenticated-orcid":false,"given":"Pascal","family":"Heitel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Faudone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Helmst\u00e4dter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurema","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Tjaden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Schierle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Pollinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Merk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"key":"411_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"411_CR2","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","volume":"284","author":"M Makishima","year":"1999","unstructured":"Makishima, M. et al. Identification of a nuclear receptor for bite acids. Science 284, 1362\u20131365 (1999).","journal-title":"Science"},{"key":"411_CR3","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.1021\/jm0582221","volume":"48","author":"R Pellicciari","year":"2005","unstructured":"Pellicciari, R., Costantino, G. & Fiorucci, S. Farnesoid X receptor: from structure to potential clinical applications. J. Med. Chem. 48, 5383\u20135403 (2005).","journal-title":"J. Med. Chem."},{"key":"411_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.4155\/fmc.12.41","volume":"4","author":"S Fiorucci","year":"2012","unstructured":"Fiorucci, S., Mencarelli, A., Distrutti, E. & Zampella, A. Farnesoid X receptor: from medicinal chemistry to clinical applications. Future Med. Chem. 4, 877\u2013891 (2012).","journal-title":"Future Med. Chem."},{"key":"411_CR5","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2014","unstructured":"Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956\u2013965 (2014).","journal-title":"Lancet"},{"key":"411_CR6","doi-asserted-by":"publisher","first-page":"574.e1","DOI":"10.1053\/j.gastro.2013.05.042","volume":"145","author":"S Mudaliar","year":"2013","unstructured":"Mudaliar, S. et al. Efficacy and safety of the farnesoid x receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574.e1\u2013582.e1 (2013).","journal-title":"Gastroenterology"},{"key":"411_CR7","doi-asserted-by":"publisher","first-page":"7703","DOI":"10.1021\/acs.jmedchem.7b00398","volume":"60","author":"J Schmidt","year":"2017","unstructured":"Schmidt, J. et al. A dual modulator of farnesoid X receptor and soluble epoxide hydrolase to counter nonalcoholic steatohepatitis. J. Med. Chem. 60, 7703\u20137724 (2017).","journal-title":"J. Med. Chem."},{"key":"411_CR8","doi-asserted-by":"publisher","first-page":"8035","DOI":"10.1021\/jm500937v","volume":"57","author":"D Merk","year":"2014","unstructured":"Merk, D. et al. Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid x receptor modulators: development of a highly potent partial farnesoid x receptor agonist. J. Med. Chem. 57, 8035\u20138055 (2014).","journal-title":"J. Med. Chem."},{"key":"411_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bmcl.2010.11.039","volume":"21","author":"HGF Richter","year":"2011","unstructured":"Richter, H. G. F. et al. Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes. Bioorg. Med. Chem. Lett. 21, 191\u2013194 (2011).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"411_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10853-2","volume":"10","author":"D Merk","year":"2019","unstructured":"Merk, D. et al. Molecular tuning of farnesoid X receptor partial agonism. Nat. Commun. 10, 2915 (2019).","journal-title":"Nat. Commun."},{"key":"411_CR11","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1124\/pr.58.4.5","volume":"58","author":"L Michalik","year":"2006","unstructured":"Michalik, L. et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 58, 726\u2013741 (2006).","journal-title":"Pharmacol. Rev."},{"key":"411_CR12","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","volume":"62","author":"M Pawlak","year":"2015","unstructured":"Pawlak, M., Lefebvre, P. & Staels, B. Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 62, 720\u2013733 (2015).","journal-title":"J. Hepatol."},{"key":"411_CR13","doi-asserted-by":"publisher","first-page":"15924","DOI":"10.1073\/pnas.0306981100","volume":"100","author":"T Tanaka","year":"2003","unstructured":"Tanaka, T. et al. Activation of peroxisome proliferator-activated receptor induces fatty acid -oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl Acad. Sci. USA 100, 15924\u201315929 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"411_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0092-8674(03)00269-1","volume":"113","author":"YX Wang","year":"2003","unstructured":"Wang, Y. X. et al. Peroxisome-proliferator-activated receptor \u03b4 activates fat metabolism to prevent obesity. Cell 113, 159\u2013170 (2003).","journal-title":"Cell"},{"key":"411_CR15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/hep4.1072","volume":"1","author":"F Haczeyni","year":"2017","unstructured":"Haczeyni, F. et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol. Commun. 1, 663\u2013674 (2017).","journal-title":"Hepatol. Commun."},{"key":"411_CR16","doi-asserted-by":"publisher","first-page":"1147.e5","DOI":"10.1053\/j.gastro.2016.01.038","volume":"150","author":"V Ratziu","year":"2016","unstructured":"Ratziu, V. et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150, 1147.e5\u20131159.e5 (2016).","journal-title":"Gastroenterology"},{"key":"411_CR17","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394, 2184\u20132196 (2019).","journal-title":"Lancet"},{"key":"411_CR18","first-page":"501","volume":"19","author":"A Mullard","year":"2020","unstructured":"Mullard, A. FDA rejects NASH drug. Nat. Rev. Drug Discov. 19, 501 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"411_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45178-z","volume":"9","author":"JD Roth","year":"2019","unstructured":"Roth, J. D. et al. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob\/ob mouse model of biopsy-confirmed NASH. Sci. Rep. 9, 9046 (2019).","journal-title":"Sci. Rep."},{"key":"411_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.bmc.2014.12.013","volume":"23","author":"D Merk","year":"2015","unstructured":"Merk, D. et al. Anthranilic acid derivatives as nuclear receptor modulators - development of novel PPAR selective and dual PPAR\/FXR ligands. Bioorg. Med. Chem. 23, 499\u2013514 (2015).","journal-title":"Bioorg. Med. Chem."},{"key":"411_CR21","doi-asserted-by":"publisher","first-page":"E2563","DOI":"10.1073\/pnas.1621513114","volume":"114","author":"C-C Wu","year":"2017","unstructured":"Wu, C.-C. et al. Structural basis for specific ligation of the peroxisome proliferator-activated receptor \u03b4. Proc. Natl Acad. Sci. USA 114, E2563\u2013E2570 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"411_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1021\/jm058056x","volume":"50","author":"ML Sierra","year":"2007","unstructured":"Sierra, M. L. et al. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. J. Med. Chem. 50, 685\u2013695 (2007).","journal-title":"J. Med. Chem."},{"key":"411_CR23","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1021\/acs.jmedchem.8b01848","volume":"62","author":"J Pollinger","year":"2019","unstructured":"Pollinger, J. et al. Tuning nuclear receptor selectivity of Wy14,643 towards selective retinoid X receptor modulation. J. Med. Chem. 62, 2112\u20132126 (2019).","journal-title":"J. Med. Chem."},{"key":"411_CR24","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/2472555220923979","volume":"25","author":"A Howarth","year":"2020","unstructured":"Howarth, A. et al. HighVia\u2014a flexible live-cell high-content screening pipeline to assess cellular toxicity. SLAS Discov. 25, 801\u2013811 (2020).","journal-title":"SLAS Discov."},{"key":"411_CR25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","volume":"62","author":"E Proschak","year":"2019","unstructured":"Proschak, E., Stark, H. & Merk, D. Polypharmacology by design: a medicinal chemist\u2019s perspective on multitargeting compounds. J. Med. Chem. 62, 420\u2013444 (2019).","journal-title":"J. Med. Chem."},{"key":"411_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","volume":"24","author":"KS T\u00f8lb\u00f8l","year":"2018","unstructured":"T\u00f8lb\u00f8l, K. S. et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J. Gastroenterol. 24, 179\u2013194 (2018).","journal-title":"World J. Gastroenterol."},{"key":"411_CR27","doi-asserted-by":"crossref","unstructured":"Sasaki, Y. et al. Pemafibrate, a selective PPAR\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content. Sci. Rep. 10, 7818 (2020).","DOI":"10.1038\/s41598-020-64902-8"},{"key":"411_CR28","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/liv.13634","volume":"38","author":"MR Jain","year":"2018","unstructured":"Jain, M. R. et al. Dual PPAR\u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int. 38, 1084\u20131094 (2018).","journal-title":"Liver Int."},{"key":"411_CR29","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1055\/s-2006-946680","volume":"72","author":"O Rau","year":"2006","unstructured":"Rau, O. et al. Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator-activated receptor gamma. Planta Med. 72, 881\u2013887 (2006).","journal-title":"Planta Med."},{"key":"411_CR30","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.bmcl.2017.01.066","volume":"27","author":"P Heitel","year":"2017","unstructured":"Heitel, P., Achenbach, J., Moser, D., Proschak, E. & Merk, D. DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators. Bioorg. Med. Chem. Lett. 27, 1193\u20131198 (2017).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"411_CR31","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1021\/acs.jmedchem.7b00903","volume":"60","author":"D Flesch","year":"2017","unstructured":"Flesch, D. et al. Non-acidic farnesoid X receptor modulators. J. Med. Chem. 60, 7199\u20137205 (2017).","journal-title":"J. Med. Chem."},{"key":"411_CR32","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.bcp.2012.02.027","volume":"83","author":"R Steri","year":"2012","unstructured":"Steri, R., Achenbach, J., Steinhilber, D., Schubert-Zsilavecz, M. & Proschak, E. Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem. Pharmacol. 83, 1674\u20131681 (2012).","journal-title":"Biochem. Pharmacol."},{"key":"411_CR33","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.bbalip.2007.04.007","volume":"1771","author":"S Seuter","year":"2007","unstructured":"Seuter, S., V\u00e4is\u00e4nen, S., R\u00e5dmark, O., Carlberg, C. & Steinhilber, D. Functional characterization of vitamin D responding regions in the human 5-Lipoxygenase gene. Biochim. Biophys. Acta 1771, 864\u2013872 (2007).","journal-title":"Biochim. Biophys. Acta"},{"key":"411_CR34","doi-asserted-by":"publisher","first-page":"28857","DOI":"10.1074\/jbc.M011610200","volume":"276","author":"M Ananthanarayanan","year":"2001","unstructured":"Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D. J. & Suchy, F. J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor\/bile acid receptor. J. Biol. Chem. 276, 28857\u201328865 (2001).","journal-title":"J. Biol. Chem."},{"key":"411_CR35","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1021\/acsmedchemlett.9b00306","volume":"10","author":"J Pollinger","year":"2019","unstructured":"Pollinger, J. et al. A novel biphenyl-based chemotype of retinoid X receptor ligands enables subtype and heterodimer preferences. ACS Med. Chem. Lett. 10, 1346\u20131352 (2019).","journal-title":"ACS Med. Chem. Lett."},{"key":"411_CR36","first-page":"1186.e4","volume":"25","author":"W Fan","year":"2017","unstructured":"Fan, W. et al. PPAR\u03b4 promotes running endurance by preserving glucose. Cell Metab. 25, 1186.e4\u20131193.e4 (2017).","journal-title":"Cell Metab."},{"key":"411_CR37","doi-asserted-by":"crossref","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","DOI":"10.1002\/hep.20701"}],"container-title":["Communications Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42004-020-00411-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42004-020-00411-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42004-020-00411-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T03:19:03Z","timestamp":1670383143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42004-020-00411-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["411"],"URL":"https:\/\/doi.org\/10.1038\/s42004-020-00411-z","relation":{},"ISSN":["2399-3669"],"issn-type":[{"value":"2399-3669","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,13]]},"assertion":[{"value":"4 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.H., G.F., J.S., and D.M. are inventors of the patent Johann Wolfgang Goethe-Universit\u00e4t, Dual agonists of FXR and PPAR and their uses, WO2019057969A1, 2019, which claims compounds described in this study. There are no further competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}